5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

Bibliographic Details
Main Authors:	Craddock, C, Goardon, N, Griffiths, M, Cavenagh, J, Siddique, S, Vyas, P
Format:	Conference item
Published:	2008

Similar Items

5 ' AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS
by: Craddock, C, et al.
Published: (2009)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
by: Craddock, C, et al.
Published: (2013)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
by: Craddock, C, et al.
Published: (2013)

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.
by: Bradbury, C, et al.
Published: (2014)

Clonal structures of leukaemia stem cell populations in myeloid blast phase chronic myeloid leukaemia
by: Karamitros, D, et al.
Published: (2016)

FACTORS DETERMINING CLINICAL RESPONSE TO 5 '-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA
by: Craddock, C, et al.
Published: (2010)

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia
by: Craddock, C, et al.
Published: (2011)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
by: Goodyear, O, et al.
Published: (2010)

Selective Persistence of Distinct Stem/B Leukaemic Stem Cells In Childhood Acute Lymphoblastic Leukaemia In Clinical Remission
by: Lutz, C, et al.
Published: (2010)

CD44‐targeted chimeric antigen receptor‐T eradicates acute myeloid leukaemic stem cells
by: Linah A. Shahoumi
Published: (2022-12-01)

The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia
by: Mehdi Ghasemi, et al.
Published: (2019-05-01)

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
by: Goodyear, O, et al.
Published: (2010)

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
by: Loke, J, et al.
Published: (2021)

Leukaemic Transformation of Multiple Myeloma in Post Chemotherapy Remission Phase
by: Palak Agarwal, et al.
Published: (2016-04-01)

FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
by: Ai Asai-Nishishita, et al.
Published: (2023-09-01)

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
by: Craddock, C, et al.
Published: (2016)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
by: John F. Seymour, et al.
Published: (2017-12-01)

Persistence of UBTF tandem duplications in remission in acute myeloid leukaemia
by: Sean Harrop, et al.
Published: (2023-11-01)

Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia
by: Lutz, C, et al.
Published: (2013)

Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia.
by: Lutz, C, et al.
Published: (2013)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
by: Waldmann, H, et al.
Published: (1987)

Testicular leukaemic infiltration in relapsed acute lymphoblastic leukaemia: a case report
by: Abdul Qadir Qader, et al.
Published: (2024-01-01)

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
by: Craddock, C, et al.
Published: (2017)

Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?
by: Carolyn S. Grove, et al.
Published: (2014-08-01)

Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
by: Craddock, C, et al.
Published: (2017)

Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cellsResearch in context
by: Josep M. Cornet-Masana, et al.
Published: (2019-09-01)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
by: Hamid Ehsan, et al.
Published: (2022-01-01)

Diffuse Large B-Cell Lymphoma Relapsing in Leukaemic Phase Presenting as Acute Leukaemia
by: Priyavadhana Balasubramanian, et al.
Published: (2019-01-01)

Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
by: Miriam Saiz-Rodríguez, et al.
Published: (2021-11-01)

Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia
by: Pierre Hirsch, et al.
Published: (2016-08-01)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
by: Denise Maravalle, et al.
Published: (2022-05-01)

Expression of Aberrant Markers and its Association with Remission Postinduction Therapy in Acute Lymphoblastic Leukaemia and Acute Myeloid Leukaemia
by: Subbaramaiah Shwetha, et al.
Published: (2021-07-01)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
by: Goodyear, O, et al.
Published: (2012)

S150: TIMING AND CLONAL TRAJECTORY TO CHRONIC MYELOID LEUKAEMIA DRIVEN BY THE PHILADELPHIA CHROMOSOME
by: Aleksandra Kamizela, et al.
Published: (2023-08-01)

Genetic and epigenetic basis of clonal advantage during the evolution of acute myeloid leukaemia
by: Turkalj, S
Published: (2024)

P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA
by: Wing Lam, et al.
Published: (2023-08-01)

Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients
by: Ulf Schmitz, et al.
Published: (2020-12-01)

P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON
by: E. N. Oliva, et al.
Published: (2022-06-01)